In these studies, influenza VLPs were generated in a recombinant baculovirus system (93, 94) and modified, on one hand, with either GPI-anchored IL12, GM-CSF, or ICAM-1 (collectively termed GPI immunostimulatory molecules) as adjuvant agents in anti-viral immune responses (19) and, on the other hand, with GPI-HER2 as a model for protein transfer of a tumor-associated antigen for tumor vaccination (36). The gene discussed is ICAM1; the disease is neoplasm.